Skip to main content

Table 3 Meth-evoked motor activity: SDZ Ser 082 and SB 206553 effects

From: SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats

 

Horizontal Activity

Total Distance

Vertical Activity

Stereotypy Count

Vehicle

8797 ± 738

3832 ± 336

1142 ± 122

477 ± 33

1.0 mg/kg SDZ

8598 ± 858

3723 ± 392

996 ± 190

460 ± 29

Vehicle

7448 ± 1025

3113 ± 444

797 ± 141

446 ± 29

5.0 mg/kg SB206

9067 ± 711

4326 ± 572

594 ± 120

471 ± 18

Vehicle

8429 ± 1133

3705 ± 692

1124 ± 201

471 ± 26

10.0 mg/kg SB206

6448 ± 1276

2245 ± 499

398 ± 91**

394 ± 58

  1. Rats that had undergone repeated cue reactivity testing were withdrawn from methamphetamine and assessed for methamphetamine-evoked (1.0 mg/kg) motor effects after a 30 min pretreatment with 1.0 mg/kg SDZ Ser 082 (SDZ; 5-HT2C receptor antagonist), 5.0 mg/kg SB 206553 (SB206; putative 5-HT2C receptor inverse agonist), 10.0 mg/kg SB206 and respective vehicles. Serotonin2C receptor antagonism had no effect on methamphetamine-evoked motor activity whereas inverse agonism with 10.0 mg/kg SB206 significantly attenuated vertical activity (paired t-test; **p < 0.01).